RAF/RAS oncogenes and mismatch-repair status
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Genes of the RAF family encode kinases that are regulated by Ras and mediate cellular responses to growth signals. Activating mutations in one RAF gene, BRAF, have been found in a high proportion of melanomas and in a small fraction of other cancers. Here we show that BRAF mutations in colorectal cancers occur only in tumours that do not carry mutations in a RAS gene known as KRAS, and that BRAF mutation is linked to the proficiency of these tumours in repairing mismatched bases in DNA. Our results not only provide genetic support for the idea that mutations in BRAF and KRAS exert equivalent effects in tumorigenesis, but also emphasize the role of repair processes in establishing the mutation spectra that underpin human cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The prevalence of BRAF V600E mutations in mCRC is 8–10%, and they occur only in KRAS-WT mCRC [159,160].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [160]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Lessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Self-citationStabilization of β-Catenin by Genetic Defects in Melanoma Cell Lines
Rubinfeld, B., Robbins, P., El-Gamil, M., Albert, I., Porfiri, E., & Polakis, P. (1997) · Science · doi:10.1126/science.275.5307.1790 · Cited by 1,223
Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer.
Sparks, A. B., Morin, P. J., Vogelstein, B., & Kinzler, K. W. (1998) · PubMed · Cited by 1,008
Self-citationDifferential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases
Marais, R., Light, Y., Paterson, H. F., Mason, C. S., & Marshall, C. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4378 · Cited by 456
Mechanisms underlying losses of heterozygosity in human colorectal cancers
Thiagalingam, S., Laken, S., Willson, J. K. V., Markowitz, S. D., Kinzler, K. W., Vogelstein, B., & Lengauer, C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051625398 · Cited by 228
Self-citationPrevalence of somatic alterations in the colorectal cancer cell genome
Wang, T.-L., Rago, C., Silliman, N., Ptak, J., Markowitz, S., Willson, J. K. V., Parmigiani, G., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261714699 · Cited by 177
Self-citationOncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors
Storm, S. M., & Rapp, U. R. (1993) · Toxicology Letters · doi:10.1016/0378-4274(93)90056-4 · Cited by 53
Research works printed but not linked: 2
- Sparks, A. B., Morin, P. J., Vogelstein, B. & Kinzler, K. W. Cancer Res. 58, 1130–1134 (1998).
- Markowitz, S. J. Clin. Oncol. 18 (suppl.), 75–80 (2000).
Cited by
Items 301–400 of 999
Custodio, A., & Feliú, J. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.05.001 · Cited by 110
“[169] Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B,”
BackgroundBiomarkers in precision therapy in colorectal cancer
Reimers, M. S., Zeestraten, E. C. M., Kuppen, P. J. K., Liefers, G., & van de Velde, C. J. �. (2013) · Gastroenterology report · doi:10.1093/gastro/got022 · Cited by 105
“The BRAF gene encodes a serine/threonine protein kinase belonging to the RAS-RAF-MEK-ERK kinase pathway regulated by KRAS protein activity and involved in CRC development [55, 56].”
BackgroundThompson, B. A., Goldgar, D. E., Paterson, C., Clendenning, M., Walters, R., Arnold, S., Parsons, M. T., Michael D., W., Gallinger, S., Haile, R. W., et al. (2013) · Human Mutation · doi:10.1002/humu.22213 · Cited by 95
“[Val600Glu]) is frequently present in MSI-H cancers with MLH1 methylation [Davies et al., 2002; Rajagopalan et al., 2002], but not in MSI-H cancers arising in patients with a germline MMR gene pathogenic variant [Deng et al.”
BackgroundBRAF Mutations: Signaling, Epidemiology, and Clinical Experience in Multiple Malignancies
Hall, R. D., & Kudchadkar, R. R. (2014) · Cancer Control · doi:10.1177/107327481402100307 · Cited by 93
A practical guide to biomarkers for the evaluation of colorectal cancer
Chen, W., & Frankel, W. L. (2018) · Modern Pathology · doi:10.1038/s41379-018-0136-1 · Cited by 108
BRAF and KRAS mutations in prostatic adenocarcinoma
Cho, N., Choi, M., Kim, B., Cho, Y., Moon, K. C., & Kang, G. H. (2006) · International Journal of Cancer · doi:10.1002/ijc.22071 · Cited by 94
Epigenetic epidemiology of cancer
Barrow, T. M., & Michels, K. B. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.08.002 · Cited by 101
Løes, I. M., Immervoll, H., Sørbye, H., Angelsen, J., Horn, A., Knappskog, S., & Lønning, P. E. (2016) · International Journal of Cancer · doi:10.1002/ijc.30089 · Cited by 102
Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls
Lamy, A., Blanchard, F., Pessot, F. L., Sesboüé, R., Fiore, F. D., Bossut, J., Fiant, E., Frébourg, T., & Sabourin, J. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.60 · Cited by 101
“As expected, KRAS and BRAF mutations were found to be mutually exclusive”
BackgroundMolecular Pathways: Mitogen-Activated Protein Kinase Pathway Mutations and Drug Resistance
Pritchard, A. L., & Hayward, N. K. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0383 · Cited by 112
Exploring and modelling colon cancer inter-tumour heterogeneity: opportunities and challenges
Buikhuisen, J. Y., Torang, A., & Medema, J. P. (2020) · Oncogenesis · doi:10.1038/s41389-020-00250-6 · Cited by 107
BRAF Point Mutations in Primary Melanoma Show Different Prevalences by Subtype
Sasaki, Y., Niu, C., Makino, R., Kudo, C., Sun, C., Watanabe, H. K., Matsunaga, J., Takahashi, K., Tagami, H., Aiba, S., et al. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.22722.x · Cited by 91
Role of BRAF‐V600E in the serrated pathway of colorectal tumourigenesis
Minoo, P., Moyer, M., & Jass, Jr. (2007) · The Journal of Pathology · doi:10.1002/path.2160 · Cited by 92
“Oncogenic mutations of BRAF, most frequently BRAF-V600E, have been reported in colon cancer, melanoma, papillary thyroid carcinoma and other cancers [41,42].”
BackgroundDermatological findings in 61 mutation-positive individuals with cardiofaciocutaneous syndrome
Siegel, D. H., McKenzie, J., Frieden, I. J., & Rauen, K. A. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2010.10122.x · Cited by 99
Bessa, X., Ballesté, B., Andreu, M. G., Castells, A., Bellosillo, B., Balaguer, F., Castellví-Bel, S., Payá, A., Jover, R., Alenda, C., et al. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.10.011 · Cited by 92
Mutation analysis of B-RAF gene in human gliomas
Basto, D., Trovisco, V., Lopes, J. M., Martins, A. M., Pardal, F., Soares, P., & Reis, R. M. (2004) · Acta Neuropathologica · doi:10.1007/s00401-004-0936-x · Cited by 90
“Although the oncogenic potential of RAF (particularly of C-RAF in in vitro models) has been known for a long time [15], it is only recently that a large-scale screen for genes mutated in cancer has reported the presence of somatic B-RAF mutations in human tumors, including melanomas, colorectal, lung and thyroid cance…”
BackgroundKumar, R., Angelini, S., & Hemminki, K. (2003) · Oncogene · doi:10.1038/sj.onc.1206909 · Cited by 90
“These data, though limited, are contrary to an earlier report on colorectal tumours, which had suggested an association of BRAF mutations with microsatellite instability (Rajagopalan et al., 2002).”
ResultMartinelli, E., Troiani, T., Morgillo, F., Rodolico, G., Vitagliano, D., Morelli, M. P., Tuccillo, C., Vecchione, L., Capasso, A., Orditura, M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0923 · Cited by 89
Colorectal Cancer: Chemopreventive Role of Curcumin and Resveratrol
Patel, V. B., Misra, S., Patel, B. B., & Majumdar, A. P. N. (2010) · Nutrition and Cancer · doi:10.1080/01635581.2010.510259 · Cited by 98
“There are two distinct pathways in the development of CRC: 1) chromosomal instability, which is characterized by loss of heterozygosity (LOH), is responsible for 80–85% of sporadic colorectal adenomas and carcinomas; and 2) Microsatellite instability (MSI), which is responsible for 15–20% of sporadic CRCs (8).”
BackgroundCopy Number Analysis Identifies Novel Interactions Between Genomic Loci in Ovarian Cancer
Gorringe, K. L., George, J., Anglesio, M. S., Ramakrishna, M., Etemadmoghadam, D., Cowin, P. A., Sridhar, A., Williams, L. H., Boyle, S. E., Yanaihara, N., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011408 · Cited by 96
“The paradigm for mutually exclusive aberrations targeting the same pathway was set in colorectal tumours for APC and CTNNB1 mutations [4] and extended in other examples such as exclusivity of BRAF and KRAS mutations [5].”
BackgroundCD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers
Harvey, J. B., Phan, L. H., Villarreal, O. E., & Bowser, J. L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00508 · Cited by 92
Cagnol, S., & Rivard, N. (2012) · Oncogene · doi:10.1038/onc.2012.88 · Cited by 94
B-RAF Regulation of Rnd3 Participates in Actin Cytoskeletal and Focal Adhesion Organization
Klein, R. M., Spofford, L. S., Abel, E. V., Ortiz, A., & Aplin, A. E. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-09-0895 · Cited by 89
“Mutations in B-RAF have been found in ϳ70% of melanomas, 35% of thyroid carcinomas, 14% of borderline ovarian cancers, and 11% of colorectal cancers (Davies et al., 2002; Rajagopalan et al., 2002; Kimura et al., 2003).”
BackgroundAdjuvant colon cancer chemotherapy: where we are and where we'll go
Lombardi, L., Morelli, F., Cinieri, S., Santini, D., Silvestris, N., Fazio, N., Orlando, L., Tonini, G., Colucci, G., & Maiello, E. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)70018-9 · Cited by 97
Opportunities for immunotherapy in microsatellite instable colorectal cancer
Westdorp, H., Fennemann, F. L., Weren, R. D. A., Bisseling, T. M., Ligtenberg, M. J. L., Figdor, C. G., Schreibelt, G., Hoogerbrugge, N., Wimmers, F., & de Vries, I. J. M. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1832-7 · Cited by 96
“The activating p.V600E hotspot mutation in BRAF is strongly associated with MMR-deficient CRC [44, 45], but is only observed in sporadic MSI CRC and not in MSI CRC derived from LS patients [46].”
BackgroundXiao, D., Li, Y., Tian, T., Zhang, T., Shi, S., Lu, B., Gao, Y., Qin, X., Zhang, M., Wei, W., et al. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c23005 · Cited by 89
Petti, C., Molla, A., Vegetti, C., Ferrone, S., Anichini, A., & Sensi, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4671 · Cited by 88
Activation and Involvement of Ral GTPases in Colorectal Cancer
Martin, T. D., Samuel, J. C., Routh, E. D., Der, C. J., & Yeh, J. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1517 · Cited by 88
“functional role of these effectors in cancer growth comes from the identification of mutationally activated B-Raf (8,9) or the p110α catalytic subunit of PI3K (10) in CRC.”
BackgroundHereditary Hormone Excess: Genes, Molecular Pathways, and Syndromes
Marx, S. J., & Simonds, W. F. (2005) · Endocrine Reviews · doi:10.1210/er.2003-0037 · Cited by 92
Shields, C. E. D., White, J. R., Chung, L., Wenzel, A. N., Hicks, J. L., Tam, A. J., Chan, J. L., Dejea, C. M., Fan, H., Michel, J. H., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0770 · Cited by 91
“However, total tumors for BLM mice were significantly elevated at the end of long-term ETBF experiments (Min median tumors = 10 (range 1-45); BLM median tumors = 21 (6-54); P < 0.”
BackgroundT1799A BRAF Mutations in Conjunctival Melanocytic Lesions
Goldenberg‐Cohen, N., Cohen, Y., Rosenbaum, E., Herscovici, Z., Chowers, I., Weinberger, D., Pe’er, J., & Sidransky, D. (2005) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.04-1449 · Cited by 86
Anti-HER agents in gastric cancer: from bench to bedside
Fornaro, L., Lucchesi, M., Caparello, C., Vasile, E., Caponi, S., Ginocchi, L., Masi, G., & Falcone, A. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.81 · Cited by 91
“Of note, KRAS and BRAF mutations are mutually exclusive in CRC”
BackgroundReview Article: The Role of Ras Superfamily Proteins in Bladder Cancer Progression
OXFORD, G., & THEODORESCU, D. (2003) · Journal of Urology · doi:10.1097/01.ju.0000088670.02905.78 · Cited by 86
Molecular pathogenesis of thyroid cancer
Segev, D. L., Umbricht, C. B., & Zeiger, M. A. (2003) · Surgical Oncology · doi:10.1016/s0960-7404(03)00037-9 · Cited by 107
“Similar findings have been described in colorectal tumors [106] and, recently, in thyroid tumors.”
ResultSveen, A., Johannessen, B., Tengs, T., Danielsen, S. A., Eilertsen, I. A., Lind, G. E., Berg, K. C. G., Leithe, E., Meza-Zepeda, L. A., Domingo, E., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0434-0 · Cited by 85
“The mutation profiles of MSI+ CRCs differ from those of microsatellite stable (MSS) CRCs, for example, by a strong enrichment for BRAF mutations [18].”
Bläker, H., Alwers, E., Arnold, A., Herpel, E., Tagscherer, K. E., Roth, W., Jansen, L., Walter, V., Kloor, M., Chang-Claude, J. C., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.04.015 · Cited by 89
Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer
Sawada, K., Nakamura, Y., Yamanaka, T., Kuboki, Y., Yamaguchi, D., Yuki, S., Yoshino, T., Komatsu, Y., Sakamoto, N., Okamoto, W., et al. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.05.006 · Cited by 85
High Incidence of Thyroid Cancer in Long-Standing Goiters with Thyroglobulin Mutations
Hishinuma, A., Fukata, S., Kakudo, K., Murata, Y., & Ieiri, T. (2005) · Thyroid · doi:10.1089/thy.2005.15.1079 · Cited by 85
“The other mutation, K600E, is a rare mutation only reported in one case of colorectal cancer (42).”
Immervoll, H., Hoem, D., Kugarajh, K., Steine, S. J., & Molven, A. (2006) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-006-0191-8 · Cited by 91
“Examples include malignant melanoma [1, 11], papillary thyroid carcinoma [13], hyperplasic polyps and serrated adenomas of the colon [10, 22], colorectal carcinomas [32, 35], small intestinal adenocarcinomas [6], Barrett’s adenocarcinoma [43], and gallbladder carcinomas [39].”
BackgroundGenetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer
Miranda, E., Destro, A., Malesci, A., Balladore, E., Bianchi, P. P., Baryshnikova, E., Franchi, G., Morenghi, E., Laghi, L., Gennari, L., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603337 · Cited by 94
“As previously noted (Rajagopalan et al, 2002; Yuen et al, 2002), K-Ras and B-Raf mutations appear to be mutually exclusive, confirming previous suggestions that they have similar biological targets in the RAS-RAF-MEK-ERK-MAP kinase signalling pathway (Yuen et al, 2002).”
BackgroundNew trends in molecular and cellular biomarker discovery for colorectal cancer
Aghagolzadeh, P., & Radpour, R. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i25.5678 · Cited by 95
Genetic Basis for Susceptibility to Lung Cancer
Yokota, J., Shiraishi, K., & Kohno, T. (2010) · Advances in cancer research · doi:10.1016/b978-0-12-380890-5.00002-8 · Cited by 104
Lemieux, É., Bergeron, S., Durand, V., Asselin, C., Saucier, C., & Rivard, N. (2009) · International Journal of Cancer · doi:10.1002/ijc.24485 · Cited by 97
“First, mutations of BRAF, a member of the Raf family, are associated with increased kinase activity and have been found in 9–11% of colorectal cancers; many of those with such mutations are at early Dukes’ stage (A and B).(11,12) Furthermore, BRAF mutations are frequently identified in sporadic colorectal cancer with…”
BackgroundMolecular classification and genetic pathways in hyperplastic polyposis syndrome
Carvajal‐Carmona, L., Howarth, K., Lockett, M., Polanco-Echeverry, G. M., Volikos, E., Gorman, M., Barclay, E., Martin, L., Jones, A., Saunders, B., et al. (2007) · The Journal of Pathology · doi:10.1002/path.2187 · Cited by 84
Sinicrope, F. A., Mahoney, M. R., Yoon, H. H., Smyrk, T. C., Thibodeau, S. N., Goldberg, R. M., Nelson, G. D., Sargent, D. J., & Alberts, S. R. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0527 · Cited by 84
“CIN tumors are enriched in KRAS mutations that occur as early events during tumorigenesis (3).”
CDX2 is an amplified lineage-survival oncogene in colorectal cancer
Salari, K., Spulak, M. E., Cuff, J., Forster, A. D., Giacomini, C. P., Huang, S., Ko, M. E., Lin, A. Y., van de Rijn, M., & Pollack, J. R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206004109 · Cited by 98
“Cancer Epidemiol Biomarkers Prev 13(7): 1206–1214.”
BackgroundInfluentialFeng, Y.-Z., Shiozawa, T., Miyamoto, T., Kashima, H., Kurai, M., 鈴木, 昭., & Konishi, I. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2670 · Cited by 81
“This pattern resembles that observed in colorectal carcinoma because the prevalence of BRAF mutations in colorectal adenomas ranged from 1% to 3%, and in carcinomas from 5% to 10% (8, 9).”
BackgroundTelomeres, telomerase and colorectal cancer
Bertorelle, R. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i8.1940 · Cited by 82
Genomic instability and the selection of treatments for cancer
Martin, S. A., Hewish, M., Lord, C. J., & Ashworth, A. (2010) · The Journal of Pathology · doi:10.1002/path.2631 · Cited by 82
“These sporadically occurring MSI tumours are also frequently associated with a CpG island methylator phenotype [13] and with a V600E substitution in the BRAF oncogene [14].”
BackgroundModeling Mutual Exclusivity of Cancer Mutations
Szczurek, E., & Beerenwinkel, N. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003503 · Cited by 77
“Such mutually exclusive alterations have frequently been observed in cancer data [8–10] and were associated with functional pathways or synthetic lethality [3– 8,11,12].”
BackgroundBRAF mutation is a prognostic biomarker for colorectal liver metastasectomy
Teng, H., Huang, Y.-C., Lin, J., Chen, W., Lin, T., Jiang, J., Yen, C., Li, A. F., Wang, H., Chang, S., et al. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23063 · Cited by 91
“None of our patients carried both a KRAS and a BRAF mutation, which is similar to previous reports of metastatic colorectal cancer [17,29,30].”
ResultMyricetin is a potent chemopreventive phytochemical in skin carcinogenesis
Kang, N. J., Jung, S. K., Lee, K. W., & Lee, H. J. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06122.x · Cited by 86
B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas
Trovisco, V., Soares, P., & Sobrinho-Simões, M. A. (2006) · Human Pathology · doi:10.1016/j.humpath.2006.03.013 · Cited by 90
Cutsem, E. V., Dicato, M. A., Arber, N., Berlin, J. D., Cervantes, A. M. R., Ciardiello, F., de Gramont, A., Díaz‐Rubio, E., Ducreux, M. P., Geva, R., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq273 · Cited by 86
Svrcek, M., El-Bchiri, J., Chalastanis, A., Capel, É., Dumont, S., Buhard, O., Oliveíra, C., Seruca, R., Bossard, C., Mosnier, J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.9744 · Cited by 88
Ikenoue, T., Terakado, Y., Nakagawa, H., Hikiba, Y., Fujii, T., Matsubara, D., Noguchi, R., Zhu, C., Yamamoto, K., Kudo, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep23899 · Cited by 90
Molecular Differences between Sporadic Serrated and Conventional Colorectal Adenomas
Konishi, K., Yamochi, T., Makino, R., Kaneko, K., Yamamoto, T., Nozawa, H., Katagiri, A., Ito, H., Nakayama, K., Ota, H., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0334 · Cited by 80
Mahasneh, A., Al-Shaheri, F., & Jamal, E. (2017) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2017.05.005 · Cited by 79
“Basically, BRAF V600 E mutation is present in about 8-10% of CRC cases (Rajagopalan et al., 2002).”
BackgroundPatient-oriented gene set analysis for cancer mutation data
Boca, S. M., Kinzler, K. W., Velculescu, V. E., Vogelstein, B., & Parmigiani, G. (2010) · Genome biology · doi:10.1186/gb-2010-11-11-r112 · Cited by 81
“Thus a tumor with a KRAS mutation generally does not also harbor a BRAF mutation, as KRAS is upstream of BRAF in the same pathway [9].”
BackgroundSelf-citationLi, W., Zhu, T., & Guan, K.-L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405730200 · Cited by 78
RetractedGarcia-Carbonero, N., Martínez‐Useros, J., Li, W., Orta, A., Pérez, N. T. I., Caramés, C., Hernández, T., Moreno, I., Serrano, G., & García‐Foncillas, J. (2020) · Cells · doi:10.3390/cells9010219 · Cited by 86
“functionally redundant or incompatible, and cells with both mutations are erased [33,34].”
BackgroundTumour MLH1 promoter region methylation testing is an effective prescreen for Lynch Syndrome (HNPCC)
Newton, K., Jorgensen, N. M., Wallace, A. J., Buchanan, D. D., Lalloo, F. I., McMahon, R. F., Hill, J., & Evans, D. G. (2014) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102552 · Cited by 79
Ikenoue, T., Hikiba, Y., Kanai, F., Aragaki, J., Tanaka, Y., Imamura, J., Imamura, T., Ohta, M., Ijichi, H., Tateishi, K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3591 · Cited by 77
“, R461I, I462S, and F467C, the residues adjacent to the conserved glycines, not the glycines themselves, are mutated (13, 14).”
Asaka, S.-I., Arai, Y., Nishimura, Y., Yamaguchi, K., Ishikubo, T., Yatsuoka, T., Tanaka, Y., & Akagi, K. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp017 · Cited by 76
Guren, T. K., Thomsen, M., Kure, E. H., Sorbye, H., Glimelius, B., Pfeiffer, P., Österlund, P., Sigurdsson, F., Lothe, I. M. B., Dalsgaard, A. M., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.93 · Cited by 74
“As KRAS and BRAF mutations were considered to be mutually exclusive (Rajagopalan et al, 2002), tumour DNA from the remaining 223 KRAS (exon 2)/BRAF wild-type patients was analysed for the other KRAS mutations (in exons 3 and 4) and NRAS mutations (in exons 2, 3, and 4).”
Modeling Mutual Exclusivity of Cancer Mutations
Szczurek, E., & Beerenwinkel, N. (2014) · Lecture notes in computer science · doi:10.1007/978-3-319-05269-4_24 · Cited by 70
Identification of Candidate Oncogenes in Human Colorectal Cancers With Microsatellite Instability
Gylfe, A. E., Kondelin, J., Turunen, M. M., Ristolainen, H., Katainen, R., Pitkänen, E., Kaasinen, E., Rantanen, V., Tanskanen, T. J., Varjosalo, M. T., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.015 · Cited by 77
Diep, C. H., Muñoz, R. M., Choudhary, A. K., Hoff, D. D. V., & Han, H. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2214 · Cited by 82
Brim, H., Mokarram, P., Naghibalhossaini, F., Saberifiroozi, M., Al-Mandhari, M., Al-Mawaly, K., Al-Mjeni, R., Alsayegh, A., Raeburn, S., Lee, E. W., et al. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-68 · Cited by 74
“Correlation between methylation pattern of the hMLH1 promoter and MSI status Among MSI-H samples, hMLH1 promoter methylation was found in 90% [ 18 ] of African American, 75% [6] of Omani and 71% [10] of Iranian tumors, confirming a previous finding of predominant methylation of these genes of the promoter in Africans…”
BackgroundFujiyoshi, K., Yamamoto, G., Takahashi, A., Arai, Y., Yamada, M., Kakuta, M., Yamaguchi, K., Akagi, Y., Nishimura, Y., Sakamoto, H., et al. (2017) · Oncology Reports · doi:10.3892/or.2016.5323 · Cited by 74
Yang, Z., Wu, X., Huang, Y., Di, M., Zheng, D., Chen, J., Ding, H., Mao, C., & Tang, J.-L. (2013) · International Journal of Cancer · doi:10.1002/ijc.28153 · Cited by 82
“PI3KCA mutations may coexist with either KRAS or BRAF mutations within the same tumor,(10) whereas KRAS and BRAF mutations appear to be mutually exclusive.(13) To date, KRAS mutations have been established as a major predictive biomarker of resistance to the treatment of mCRC with anti-EGFR MoAbs.”
BackgroundLee, D., Kim, K. J., Han, S., Lee, H. J., Rhee, Y.-Y., Bae, J. M., Cho, N., Lee, K.-H., Kim, T. Y., Oh, D., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3826-z · Cited by 81
Dysplastic Lesions in Inflammatory Bowel Disease: Molecular Pathogenesis to Morphology
Matkowskyj, K. A., Chen, Z. E., Rao, M. S., & Yang, G. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0086-ra · Cited by 83
Kumar, K., Brim, H., Giardiello, F. M., Smoot, D. T., Nouraie, M. S., Lee, E. L., & Ashktorab, H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1029 · Cited by 73
Mao, C., Zhou, J., Yang, Z., Huang, Y., Wu, X., Shen, H., Tang, J., & Chen, Q. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036653 · Cited by 75
“Mutations of KRAS and BRAF genes are frequently found to be mutually exclusive in colorectal cancer, both in Western and Chinese patients [25,26].”
Saetta, A. A., Papanastasiou, P., Michalopoulos, N., Gigelou, F., Korkolopoulou, P. A., Bei, T., & Patsouris, E. (2004) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-004-1046-9 · Cited by 71
“It is also associated with mismatch repair (MMR)-deficient colon cancers, in which it is commonly mutated [ 9 ].”
InfluentialCommon and Distinct Genomic Events in Sporadic Colorectal Cancer and Diverse Cancer Types
Martin, E. S., Tonon, G., Sinha, R., Xiao, Y., Feng, B., Kimmelman, A. C., Protopopov, A. I., Ivanova, E. V., Brennan, C., Montgomery, K. T., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2742 · Cited by 77
“Also, consistent with previous reports (8, 10), we observed a mutually exclusive pattern of BRAF and KRAS mutations with BRAF mutations predominant in MIN tumors [five of six BRAF mutant primary tumors show MSI, and all are MLH1 deficient (data not shown)].”
Genetic analysis of the kinome and phosphatome in cancer
Arena, S., Benvenuti, S., & Bardelli, A. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5205-1 · Cited by 89
Self-citationCharacterization of Ser338 Phosphorylation for Raf-1 Activation
Zang, M., Gong, J., Luo, L., Zhou, J., Xiang, X., Huang, W., Huang, Q., Luo, X., Olbrot, M., Peng, Y., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802855200 · Cited by 80
Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis
Kim, K., Suh, K., Kang, D., & Kang, D. (2005) · Pathology International · doi:10.1111/j.1440-1827.2005.01866.x · Cited by 71
Park, J. H., Han, S., Oh, D., Im, S., Jeong, S., Park, K. J., Kim, T., Bang, Y., & Park, J.-G. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1586-z · Cited by 77
BRAF mutations in colorectal carcinoma suggest two entities of microsatellite‐unstable tumors
Lubomierski, N., Plotz, G., Wormek, M., Engels, K., Kriener, S., Trojan, J., Jüngling, B., Zeuzem, S., & Raedle, J. (2005) · Cancer · doi:10.1002/cncr.21266 · Cited by 70
Naguib, A., Mitrou, P. N., Gay, L. J., Cooke, J. C., Luben, R., Ball, R. Y., McTaggart, A., Arends, M. J., & Rodwell, S. A. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-99 · Cited by 70
“The mutually exclusive nature of these two mutation types, as shown in this and other studies [3,5,7,18,36] may explain this: increased prevalence of BRAF mutation in this sample set may be consistent with a reduction in K-ras mutation frequency.”
BackgroundResultMori, Y., Yin, J., Sato, F., Sterian, A., Simms, L. A., Selaru, F. M., Schulmann, K., Xu, Y. H., Olaru, A., Wang, S., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3508 · Cited by 70
“Another molecular abnormality associated with hMLH1 hypermethylation is activating mutation of BRAF, which seems to functionally compensate for the lack of KRAS mutation in MSI-H cancers (21, 22).”
BackgroundMolecular classification and molecular genetics of human lung cancers
Meyerson, M. M., Franklin, W. A., & Kelley, M. J. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.12.009 · Cited by 78
Nagaraju, G. P., Alese, O. B., Landry, J., Diaz, R., & El-Rayes, B. F. (2014) · Oncotarget · doi:10.18632/oncotarget.2484 · Cited by 69
“Constitutive activating mutations in the Ras or Raf genes occur in approximately 45 and 10% of CRC, respectively [8, 9].”
Methods of overcoming treatment resistance in colorectal cancer
Temraz, S. N., Mukherji, D., Alameddine, R. S., & Shamseddine, A. I. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.08.015 · Cited by 75
BRAF mutations in non-Hodgkin's lymphoma
Lee, J. W., Yoo, N. J., Soung, Y. H., Kim, H. S., Park, W. S., Kim, S. Y., Lee, J. H., Park, J. Y., Cho, Y. G., Kim, C. J., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601371 · Cited by 68
“…have been reported within two kinase domains (G-loop and activation segment domains), and the most common mutation is a single substitution, V599E (Brose et al, 2002; Davies et al, 2002; Naoki et al, 2002; Rajagopalan et al, 2002; Yuen et al, 2002; Pollock et al, 2003; Satyamoorthy et al, 2003).”
BackgroundMutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma
Sommerer, F., Vieth, M. W., Markwarth, A., Röhrich, K., Vomschloß, S., May, A., Ell, C., Stolte, M., Hengge, U. R., Wittekind, C., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207189 · Cited by 69
“In contrast to melanoma (Davies et al., 2002; Pollock et al., 2003), colon (Rajagopalan et al., 2002), (low-grade serous) ovarian (Singer et al., 2003), and thyroid cancer (Kimura et al., 2003), we detected BRAF mutation only in a small number of Barrett’s adenocarcinomas and precursor lesions.”
ResultPrognostic Role of microRNA-21 in Colorectal Cancer: a Meta-Analysis
Xia, X., Yang, B., Zhai, X., Liu, X., Shen, K., Wu, Z., & Cai, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080426 · Cited by 74
“Although genes associated with TP53 mutations [2], KRAS mutations [3,4], BRAF mutations [4,5], and defective DNA mismatch repair (dMMR) [6] have been investigated to confirm the prognostic and survival-predictive of CRC, the clinical use of these markers requires further research.”
BackgroundMolecular Analysis of Colorectal Tumors within a Diverse Patient Cohort at a Single Institution
Sylvester, B. E., Huo, D., Khramtsov, A., Zhang, J., Smalling, R. V., Olugbile, S. O., Polite, B. N., & Olopade, O. I. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1397 · Cited by 69
“the BRAF V600E mutation, as they respectively account for 90% of all KRASmutations and 80% of all BRAFmutations in colorectal cancers (14, 25, 26).”
BackgroundHereditary Nonpolyposis Colon Cancer
Rusin, L. C., & Galandiuk, S. (2007) · Springer eBooks · doi:10.1007/978-0-387-36374-5_38 · Cited by 67
Khan, K. H., Valeri, N., Dearman, C., Rao, S., Watkins, D. J., Starling, N., Chau, I., & Cunningham, D. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.09.001 · Cited by 75
Sclafani, F., Gullo, G., Sheahan, K. D., & Crown, J. P. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.11.003 · Cited by 76
Wickenden, J. A., Jin, H., Johnson, M., Gillings, A. S., Newson, C., Austin, M., Chell, S. D., Balmanno, K., Pritchard, C. A., & Cook, S. J. (2008) · Oncogene · doi:10.1038/onc.2008.335 · Cited by 67
“BRAFV600E is found in 10-25% of human colorectal cancers (CRC) (Davies et al., 2002; Mercer and Pritchard, 2003), early in the adenoma to carcinoma sequence (Rajagopalan et al., 2002; Yuen et al., 2002), and cancer cells harbouring BRAFV600E typically exhibit high ERK1/2 activity.”
BackgroundMhaidat, N. M., Zhang, X. D., Jiang, C. C., & Hersey, P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2216 · Cited by 72
Seth, R., Crook, S., Ibrahem, S., Fadhil, W., Jackson, D., & Ilyas, M. (2009) · Gut · doi:10.1136/gut.2008.159137 · Cited by 66
“Mutations appear to be clustered in exons 11 and 15,”
BackgroundKim, I.-J., Park, J.-H., Kang, H. C., Shin, Y., Park, H., Park, H.-R., Ku, J., Lim, S., & Park, J.-G. (2003) · Human Genetics · doi:10.1007/s00439-003-1027-0 · Cited by 66
Kang, S., Kim, H.-S., Seo, S. S., Park, S., Sidransky, D., & Dong, S. M. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.01.045 · Cited by 66
Sandmeier, D., Benhattar, J., Martin, P., & Bouzourène, H. (2009) · Histopathology · doi:10.1111/j.1365-2559.2009.03356.x · Cited by 66
“KRAS and BRAF mutations are present but mutually exclusive in most colorectal polyps and in CRCs, which indicates that both mutations occur as early events in neoplasm development and supports the idea that there are two parallel pathways that rarely cross over.(41) Prior to the recognition of SSAs, various reports yi…”
Result
Metadata
- Authors
- Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E.
- Affiliations
- Johns Hopkins University (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Velculescu, Victor E.
- Venue
- Nature
- Published
- 2002-08-29
- Volume
- 418
- Issue
- 6901
- Pages
- 934-934
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1985035689
- Cited by
- 1,224
- References
- 8
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 29 · 2023: 30 · 2022: 26 · 2021: 42 · 2020: 38 · 2019: 35 · 2018: 41 · 2017: 42 · 2016: 51 · 2015: 76 · 2014: 65 · 2013: 74 · 2012: 78
- FWCI
- 37.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- BRAF mutation, KRAS mutation, oncogenic Ras, DNA mismatch repair, colorectal cancer, melanoma, carcinogenesis, DNA repair, mutation spectrum, growth factor signaling
- MeSH terms
- DNA Damage, DNA Repair, Gene Frequency, Humans, Mutation, Oncogenes, Genes, ras, Colorectal Neoplasms, Proto-Oncogene Proteins c-raf, Base Pair Mismatch
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.